ARV drug protects people who inject from HIV

The first trial to assess whether preventative treatment with HIV drugs could affect rates of HIV infection in people who inject drugs has found that daily tablets of the tenofovir disoproxil fumarate (tenofovir), an antiretroviral (ARV) drug, reduced HIV incidence by nearly half (48.9 per cent) compared to placebo, according to new results published online first in The Lancet. A team of researchers led by Dr Kachit Choopanya, the trial’s Principal Investigator, and Dr Michael Martin, Chief of Clinical Research for the Thailand Ministry of Public Health-US CDC Collaboration, recruited more than 2,400 participants at 17 drug treatment clinics in…